Effect of Rose Odor Exposure on Ictal Apnea
NCT07116421 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2025-08-11
Summary
This study will investigate the potential benefits of rose scent in reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP) in patients with epilepsy. Participants will engage in their routine inpatient observational EEG monitoring for 24 hours followed by an additional 24 hours of observational EEG monitoring with continuous exposure to rose scent, during which an essential oil diffusor with rose scent will be placed in their hospital room. During these 48 total hours of the study, participants will wear a respiratory monitoring belt across their upper chest to measure their breathing.
Potential risks include distress or discomfort when smelling the rose scent used in the study, a physical reaction to the rose scent, and discomfort or feelings of restrictiveness when wearing the respiratory monitoring belt. The total time commitment of the study is 48 consecutive hours over the course of the participants' inpatient EMU stay, during which there will be no restrictions on daily activities during the standard inpatient EMU admission except that participants must wear their respiratory belt for a majority of this 2-day period.
Conditions
- Epilepsy
- Sudden Unexpected Death in Epilepsy
Interventions
- DRUG
-
2-phenylethanol rose scent
Name: 2-phenylethanol (rose scent). Dose: 3 drops, diffused into room air over 24 hours. Frequency: Once over 24 hours. Route of administration: Essential oil diffuser. Manufactured by: The Essential Oil Company in Portland, OR. Manufacturing details: The rose scent is purified by hydrodistillation, shelf-stable, and in terms of verification of quality has been previously used in a peer-reviewed and IRB-approved study by Woo et al (2023) published in Frontiers in Neuroscience. Preparation: The Key Personnel listed in the study's IRB will prepare the rose essential oil scent by squeezing 3 drops of the product from the manufactured bottle into the essential oil compartment of the "Aroma Ace™ MINI Diffuser" essential oil diffuser, corresponding with both the rose essential oil and diffuser manufacturers' instructions for each product respectively.
Sponsors & Collaborators
-
Vanderbilt University Medical Center
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-01
- Primary Completion
- 2026-05-08
- Completion
- 2026-05-08
Countries
- United States
Study Locations
More Related Trials
-
Consciousness Prognosis Evaluation Using Olfactory Stimulations in Comatose Patients)
NCT07127224 ·Status: RECRUITING ·Phase: NA
-
Rechargeable Implantable Vagus Nerve Stimulation System for Drug-Refractory Epilepsy
NCT05993117 ·Status: UNKNOWN ·Phase: NA
-
Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation
NCT02385526 ·Status: COMPLETED
-
Infrared Photobiomodulation in Humans With Epilepsy
NCT07145489 ·Status: RECRUITING ·Phase: NA
-
Electrical Brain Stimulation to Reduce Epileptic Seizures
NCT00344877 ·Status: COMPLETED
-
Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy
NCT03200769 ·Status: COMPLETED ·Phase: NA
-
Optimization of VNS in Epileptic Patients to Induce Cardioprotection
NCT04387435 ·Status: COMPLETED ·Phase: NA
-
A Study of Meditation as a Treatment for Epilepsy
NCT00370929 ·Status: COMPLETED ·Phase: NA
-
Breathing Rescue for SUDEP Prevention
NCT05981755 ·Status: RECRUITING ·Phase: NA
-
Optimization of the Parameters of Vagal Nerve Stimulation
NCT04693221 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy
NCT06304389 ·Status: RECRUITING ·Phase: NA
-
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
NCT01281293 ·Status: COMPLETED
-
Deep Brain Stimulation vs. Vagus Nerve Stimulation for Epileptic Spasms
NCT07010276 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Monitoring Patients With Uncontrolled Epilepsy
NCT00001149 ·Status: COMPLETED
-
Electroclinical Features of Sudden Unexpected Death in Epilepsy (SUDEP) : a Multi-center Observational Study
NCT05423990 ·Status: ENROLLING_BY_INVITATION
-
Olfactive Discriminative Ability of Dogs When Confronted With Seizure and Non-seizure Samples // Identification of Potential Biomarkers for Epilepsy in Human Sweat.
NCT04266990 ·Status: TERMINATED ·Phase: NA
-
Transcranial Direct Current to Treat Epilepsy at Home
NCT04309812 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Optimal Stimulation Parameters to Disrupt Epileptiform Activity
NCT06141668 ·Status: COMPLETED ·Phase: NA
-
Creating a Healthy L.I.F.E: Lifestyle Interventions For Epilepsy
NCT05283200 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Prompt Diagnosis and Treatment of Subclinical Seizures After Cardiac Arrest
NCT02458820 ·Status: COMPLETED ·Phase: NA
-
Efficacy of 128-channel EEG Combined With BESA Dipole Localization and Intervention on Brain Waves for Epilepsy
NCT02613234 ·Status: COMPLETED ·Phase: NA
-
Remotely Supervised tDCS for Slowing ALS Disease Progression
NCT04866771 ·Status: COMPLETED ·Phase: NA
-
Autonomic Dysfunction in Temporal Lobe Epilepsy and SUDEP
NCT06269822 ·Status: COMPLETED
-
PRediction of Vagal Nerve Stimulation EfficaCy In Drug-reSistant Epilepsy
NCT04935567 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy
NCT05493722 ·Status: RECRUITING ·Phase: EARLY_PHASE1